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Abstract
Background: The neutrophil to lymphocyte ratio (NLR) has been shown to predict short- and long-term outcomes
in ischemic stroke patients. We sought to explore the temporal profile of the plasma NLR in stroke patients treated
with intravenous thrombolysis (IVT) and its relationship with intracranial bleeding complications after thrombolysis.
Methods: A total of 189 ischemic stroke patients were prospectively enrolled. Blood samples for leukocyte,
neutrophil, and lymphocyte counts were obtained at admission and at 3–6, 12–18, and 36–48 h after IVT. Head CT
was performed on admission and repeated after 36–48 h, and a CT scan was done immediately in case of clinical
worsening. Hemorrhagic events were categorized as symptomatic intracranial hemorrhage (sICH) and parenchymal
hematomas (PH) according to previously published criteria.
Results: An increasing trend in the NLR was observed after stroke, and the NLR was higher in patients who
developed PH or sICH at 3–6, 12–18, and 36–48 h after IVT (P < 0.01) than in those without PH or sICH. The optimal
cutoff value for the serum NLR as an indicator for auxiliary diagnosis of PH and sICH was 10.59 at 12–18 h.
Furthermore, the NLR obtained at 12–18-h post-treatment was independently associated with PH (adjusted odds
ratio [OR] 1.14) and sICH (adjusted OR 1.14). In addition, patients with a NLR ≥10.59 had an 8.50-fold greater risk for
PH (95 % confidence interval [CI] 2.69–26.89) and a 7.93-fold greater risk for sICH (95 % CI 2.25–27.99) than patients
with a NLR <10.59.
Conclusions: NLR is a dynamic variable, and its variation is associated with HT after thrombolysis in stroke patients.
Keywords: Neutrophil to lymphocyte ratio (NLR), Ischemic stroke, Thrombolysis, Hemorrhagic transformation,
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Background
Multiple randomized controlled trials have demonstrated
the efficacy of intravenous recombinant tissue plasmino-
gen activator (IV rtPA) administered up to 4.5 h after the
onset of symptoms of ischemic stroke [1]. However, the
risk of hemorrhagic transformation (HT) is increased by
as much as tenfold after IV rtPA, largely due to reperfu-
sion injury and the toxic effects of rtPA [2]. In addition to
the already known indicators for HT [2], the detection
of new paradigms is still worthwhile. In addition, an
improved understanding of the prevention or early risk
assessment of rtPA-related HT may also be applicable
to other reperfusion strategies such as endovascular
therapy.
In animal studies, neutrophils have been shown to
contribute to intracerebral hemorrhaging after treatment
with rtPA following cerebral ischemia, while depletion of
neutrophils reduces blood–brain barrier (BBB) disrup-
tion and the rate of HT [3, 4]. In humans, infiltration of
matrix metalloproteinase-9 (MMP-9)-positive neutro-
phils is associated with BBB breakdown, basal lamina
type IV collagen degradation, and HT [5]. Recent studies
suggested that the initial neutrophil to lymphocyte ratio
(NLR) is associated with mortality and infarct size in
ischemic stroke [6, 7] and can predict the 90-day out-
come after endovascular therapy [8]. However, all of
these studies mainly focused on static NLR values at
baseline, which may not reflect the comprehensive dy-
namic changes of patients’ conditions. Furthermore, there
is also a lack of information on the clinical value of the
NLR in acute ischemic stroke patients treated with IV
rtPA, especially its relationship with the most serious and
common complication of IV rtPA treatment, HT.
Thus, we aimed to explore the temporal variation of
the NLR in patients and its relationship with the most
serious subtypes of HT, namely symptomatic intracranial
hemorrhage (sICH) and parenchymal hematoma (PH),
in patients with ischemic stroke treated with IV rtPA [9].
Methods
Study population
Consecutive ischemic stroke patients admitted to the
Departments of Neurology at two hospitals (Jinling
Hospital and PLA 123 Hospital, both large comprehen-
sive hospitals) from March 2012 to August 2015 were
prospectively recruited. The inclusion criteria for enroll-
ment were (1) age ≥18 years and (2) diagnosis of acute
ischemic stroke and treatment with IV rtPA within 4.5-h
post-onset. The study exclusion criteria were (1) evidence
of active infection before admission or any systemic infec-
tion that occurred during the first 48 h after treatment
with IV rtPA (41 patients); (2) cancer, chronic inflamma-
tion, autoimmune disease, or steroid therapy (6 patients);
and (3) unavailability to complete blood cell count or
medical records (8 patients discharged on the same day of
admission). At last, 189 consecutive ischemic stroke
patients were included in the current study. The study
protocol was approved by the Institutional Human
Research Ethics Committees of Jinling Hospital and PLA
123 Hospital, and all patients or their relatives gave
informed consent.
Treatment administration
IV rtPA (alteplase, 0.9 mg/kg up to a maximum of
90 mg/kg) was used with 10 % of the total dosage as a
bolus, followed by a 60-min infusion of the remaining
dose. Patients who were receiving a bridging therapy
consisting of IV rtPA followed by endovascular therapy
were also enrolled. The method of endovascular therapy,
such as local intra-arterial thrombolysis using rtPA,
mechanical thrombectomy, angioplasty, stent placement,
or multimodal endovascular therapy, was left to the dis-
cretion of the neurointerventionists.
Clinical protocol and laboratory tests
Patient’s medical history, including potential stroke risk
factors, clinical examination findings, blood and coagula-
tion test results, 12-lead electrocardiographs, and chest
radiographs were obtained at admission. Stroke severity
was assessed by a certified neurologist using the National
Institutes of Health Stroke Scale (NIHSS) at admission
and at 3–6, 12–18, and 36–48 h after treatment with IV
rtPA. Neurological deterioration was defined as death or
an increase of ≥4 points in the NIHSS score between the
two examinations [10].
Venous blood samples were obtained from all patients
at admission and at 3–6, 12–18, and 36–48 h after treat-
ment with IV rtPA. Total leukocyte, neutrophil, and
lymphocyte counts were determined using a COULTER
LH780 Hematology Analyzer (Beckman Coulter, Inc,
Orange County, CA). The NLR was calculated as the ratio
of the percentage of neutrophils over the percentage of
lymphocytes, both obtained from the same blood sample.
CT and intracranial hemorrhage
On admission, all patients underwent a CT scan within
the first 4.5 h of stroke onset. CT was repeated at 36–
48 h, and another CT scan was done immediately in
case of rapid neurological deterioration to evaluate the
presence of HT. CT images were reviewed by a neuro-
radiologist with extensive experience in acute stroke
who was blinded to patients’ medical records. PH was
defined as hemorrhage with a mass effect according to
previously published criteria [11]. sICH was defined as
any hemorrhage in the brain on the CT scan accompanied
by the presence of neurological deterioration [10].
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Statistical analysis
To compare baseline characteristics between groups
according to the presence of PH or sICH, parametric
and non-parametric comparisons were performed with
the t test, χ2 test, and Mann-Whitney U test as appro-
priate. The relation of the NLR with two endpoints was
investigated using logistic regression models. For multi-
variate analysis, we first included age and sex (model 1)
and then additionally included variables that signifi-
cantly correlated with PH or sICH in the univariate
analysis (P < 0.10; models 2 or 3). Receiver operating
characteristic (ROC) curves were used to test the over-
all discriminative ability of the NLR for PH or sICH
and to establish optimal cutoff points at which the sum
of the specificity and sensitivity was the highest. The
differences in discriminative ability were tested using
the DeLong method [12]. Finally, logistic regression
analysis was performed again with the same independ-
ent variables as in the previous model, except for values
of the NLR that were included as a binary variable
according to the cutoff point. Statistical analysis was
performed using SPSS for Windows, version 17.0 (SPSS
Inc., Chicago, IL, USA) and SAS version 9.1 (SAS Insti-
tute Inc., Cary, NC). Two-tailed significance values
were applied, and statistical significance was defined as
P < 0.05.
Results
Baseline characteristics of patients
One hundred eighty-nine patients with ischemic stroke
met the study criteria. The demographic and clinical
characteristics between the included and excluded pa-
tients are detailed in Additional file 1: Table S1. These
included cohorts from different hospitals are described
in Additional file 1: Table S2. Among the 189 patients,
28 (14.8 %) presented with PH, and 17 (9.0 %) developed
sICH. The mean time of sICH (determined by head CT)
was 12.23 ± 7.74 h after thrombolysis. The main baseline
characteristics of patients according to the presence or
absence of PH or to the presence or absence of sICH are
presented in Table 1.
Temporal profile of NLR depending on the type of HT
The NLR was obtained at four different time points: at ad-
mission, 3–6 h after rtPA treatment, 12–18 h after rtPA
treatment, and 36–48 h after rtPA treatment. The tem-
poral profiles of the NLR according to the presence of PH
or sICH are presented in Figs. 1 and 2 and Additional file
1: Table S3 and Figure S1. The NLR at admission did not
differ between patients with and without PH (P = 0.819).
Thereafter, an increasing trend in the NLR was observed
in both groups (Additional file 1: Figure S1). However, the
NLR values in the PH group were significantly higher than
Table 1 Baseline characteristics of patients according to the presence/absence of PH or sICH
No PH (n = 161) PH (n = 28) P No sICH (n = 172) sICH (n = 17) P
Age, years, mean (SD) 64.1 ± 10.3 70.1 ± 10.5 0.005 64.6 ± 10.4 68.7 ± 11.7 0.133
Females, % 59 (36.6) 7 (25.0) 0.233 60 (34.9) 6 (35.3) 0.973
Body mass index, kg/m2, mean (SD) 24.4 ± 3.1 23.9 ± 3.0 0.401 24.4 ± 3.0 24.0 ± 3.5 0.601
Hypertension, % 101 (62.7) 21 (75.0) 0.210 111 (64.5) 11 (64.7) 0.989
Diabetes, % 50 (31.1) 7 (25.0) 0.519 51 (29.7) 6 (35.3) 0.629
Hyperlipidemia, % 73 (45.3) 12 (42.9) 0.807 79 (45.9) 6 (35.3) 0.400
Previous stroke, % 14 (8.7) 5 (17.9) 0.251 17 (9.9) 2 (11.8) 1.000
Coronary artery disease, % 18 (11.2) 5 (17.9) 0.494 19 (11.0) 4 (23.5) 0.266
Atrial fibrillation, % 48 (29.8) 12 (42.9) 0.171 50 (29.1) 10 (58.8) 0.012
Current smokers, % 53 (32.9) 8 (28.6) 0.650 56 (32.6) 5 (29.4) 0.791
Ongoing antiplatelet therapy, % 9 (5.6) 7 (25.0) 0.002 12 (7.0) 4 (23.5) 0.060
SBP, mm Hg, mean (SD) 148.4 ± 18.4 154.5 ± 17.1 0.104 148.9 ± 18.2 153.2 ± 18.7 0.302
DBP, mm Hg, mean (SD) 81.4 ± 9.8 83.2 ± 10.4 0.368 81.3 ± 9.7 84.8 ± 11.2 0.163
Blood glucose, mmol/L, median (IQR) 7.2 (5.3–9.0) 7.0 (5.8–9.5) 0.133 7.0 (5.3–9.0) 8.0 (5.5–9.5) 0.645
Platelets, 109/L, mean (SD) 187.9 ± 50.8 178.9 ± 40.0 0.371 187.3 ± 49.9 179.7 ± 44.5 0.545
INR, mean (SD) 1.01 ± 0.08 1.01 ± 0.09 0.468 1.01 ± 0.08 1.03 ± 0.08 0.302
Baseline NIHSS, median (IQR) 11 (6–15) 17 (10–22.5) 0.001 12 (6–15) 13 (10–20) 0.198
Onset to treatment, min, mean (SD) 170.6 ± 48.8 183.4 ± 51.9 0.207 171.1 ± 48.9 187.2 ± 52.1 0.198
IV rtPA + endovascular therapy, % 49 (30.4) 9 (32.1) 0.856 51 (29.7) 7 (41.2) 0.326
DBP diastolic blood pressure, INR international normalized ratio, IQR interquartile range, IV rtPA intravenous recombinant tissue plasminogen activator, NIHSS
National Institutes of Health Stroke Scale, PH parenchymal hemorrhage, SBP systolic blood pressure, SD standard deviation, sICH symptomatic
intracranial hemorrhage
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those in the No PH group at 3–6, 12–18, and 36–48 h
after rtPA (P < 0.001). The temporal profile of the NLR
according to the presence of sICH was similar to that
according to the presence of PH.
Association of plasma NLR with hemorrhagic
transformation
ROC curve analysis was performed to assess the best
cutoff value of the NLR for discriminating PH and sICH
(Fig. 3 and Table 2). The optimal cutoff value of the
NLR that best distinguished the presence/absence of PH
and sICH was 10.59 at 12–18 h after rtPA treatment,
which can be obtained earlier than the NLR at 36–48 h
after rtPA. The areas under the curve (AUCs) for the abil-
ity of the NLR to predict PH or sICH were 0.833 with
78.6 % sensitivity and 79.5 % specificity and 0.814 with
76.5 % sensitivity and 75.6 % specificity, respectively.
Table 3 summarizes the results of the binary logistic
regression analysis of PH and sICH. The NLR as a
continuous variable was independently associated with a
greater risk of PH with an adjusted odds ratio (OR) of
1.17 (95 % CI, 1.10–1.26) with adjustment for age and
sex (model 1) and 1.14 (1.05–1.23) with further adjust-
ment for ongoing antiplatelet therapy and baseline
NIHSS (model 2), respectively. In addition, age (adjusted
OR 1.06, 95 % CI: 1.01–1.11; P = 0.014) and ongoing
antiplatelet therapy (adjusted OR 4.00, 95 % CI: 1.13–
14.14; P = 0.031) remained significant outcome predic-
tors for PH. Furthermore, in our study, the risk of PH
was also associated with NLR levels as a dichotomous
variable (OR 8.50, 95 % CI: 2.69–26.89; P < 0.001) after
adjustment for age, sex, ongoing antiplatelet therapy,
and baseline NIHSS (model 2). This relationship was
further confirmed in the dose-response model (Additional
file 1: Figure S2). For the binary logistic regression analysis
for sICH, similar associations were found between the
NLR and sICH. A NLR level ≥10.59 (OR 7.93, 95 % CI
2.25–27.99; P = 0.001) remained significantly associated
with sICH after adjusting for age, sex, atrial fibrillation,
and ongoing antiplatelet therapy (model 3).
Discussion
This study first shows that the NLR is a dynamic vari-
able, and its variation is associated with HT after treat-
ment with IV rtPA in patients with acute stroke. In
addition, the best discriminating value of the NLR for
PH and sICH was 10.59 or more at 12–18-h post-
treatment, which was associated with an 8.50-fold in-
creased risk for PH and a 7.93-fold increased risk for
sICH.
In previous studies, a high NLR was found to be inde-
pendently associated with an increased risk of stroke in
atrial fibrillation [13]. Moreover, the initial NLR is asso-
ciated with infarct size and mortality rate in ischemic
stroke [6, 7], and it also has predictive value for 90-day
outcome after endovascular therapy [8]. However, the
previous studies did not explore the clinical value of the
NLR in acute ischemic stroke patients treated with IV
rtPA.
Recently, Maestrini et al. reported that higher neutro-
phil counts and NLR before thrombolysis for cerebral
ischemia are independently associated with sICH and
worse outcome at 3 months [14]. However, they did not
exclude patients with previous infections, which might
contribute to the difference in the predictive values of
Fig. 1 Temporal profile of plasma neutrophil to lymphocyte ratio
(NLR) in stroke patients treated with recombinant tissue plasminogen
activator (rtPA) according to the presence of parenchymal hemorrhage
(PH). Blue boxes patients without PH, green boxes patients with PH.
*P < 0.001 between patients with and without PH
Fig. 2 Temporal profile of plasma neutrophil to lymphocyte ratio
(NLR) in stroke patients treated with recombinant tissue plasminogen
activator (rtPA) according to the presence of symptomatic intracranial
hemorrhage (sICH). Blue boxes patients without sICH, green boxes
patients with sICH. #P = 0.009 between patients with and without sICH;
##P < 0.001 between patients with and without sICH
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the baseline NLR for sICH between their study and ours.
That is because infections can lead to poor outcome
after stroke via many different mechanisms, which may
include (1) increased BBB disruption and tissue damage
by neutrophil-derived various proteases, reactive oxygen
species (ROS), as well as numerous inflammatory media-
tors; (2) impaired tissue reperfusion through endothelia-
dependent mechanisms; (3) increased platelet activation
and microvascular coagulation; and (4) CRP-induced is-
chemic tissue injury via a complement-dependent mech-
anism [15, 16]. Therefore, this shows that neutrophils
are just one of many different mechanisms, and the
association between the baseline NLR and endpoints
may disappear after adjustment for infections. The rea-
sons for such a difference may also relate to what the
NLR represents. Changes observed in the baseline NLR
could reflect the disease itself or external environment
factors such as infection or cancer. Our results and their
conclusions do not contradict per se because their study
population is different to ours, with the NLR at baseline
reflecting both the disease itself and the external envir-
onment factors in their study, but only the disease itself
in our study.
The study by Maestrini et al. has a higher statistical
power than our study based on the larger sample size
[14], and we also believe that their results are fully cred-
ible and reliable. Higher numbers of baseline neutrophils
at baseline have greater potential to induce tissue dam-
age via the release of various proteolytic enzymes, ROS,
and numerous inflammatory mediators [2]. Thus, in
theory, patients with infection or other conditions that
can potentially change baseline the NLR have a higher
Fig. 3 Discriminative ability of the neutrophil to lymphocyte ratio (NLR) for parenchymal hemorrhage (PH) and symptomatic intracranial
hemorrhage (sICH). a Receiver operator characteristic (ROC) curve for NLR in auxiliary diagnosis of PH and b ROC curve for NLR in the auxiliary
diagnosis of sICH
Table 2 Diagnostic values of the neutrophil to lymphocyte ratio (NLR) for PH and sICH
AUC (95 % CI) P Cutoff value Sensitivity (%) Specificity (%)
For PH
3–6 h NLR 0.717 (0.630–0.803) <0.001 5.45 78.6 65.2
12–18 h NLR 0.833 (0.764–0.903) Reference 10.59 78.6 79.5
36–48 h NLR 0.830 (0.758–0.902) 0.887 14.36 60.7 91.9
For sICH
3–6 h NLR 0.691 (0.597–0.785) <0.001 5.45 76.5 62.8
12–18 h NLR 0.814 (0.728–0.900) Reference 10.59 76.5 75.6
36–48 h NLR 0.766 (0.666–0.866) 0.166 14.36 52.9 87.8
AUC area under the curve, CI confidence interval, PH parenchymal hematoma, sICH symptomatic intracranial hemorrhage
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risk for the occurrence of HT after treatment with IV
rtPA. Similarly, when we reintegrate the patients with
infection or other conditions with potential to change
the NLR into our analysis, the baseline NLR is higher in
patients with HT (Additional file 1: Figure S3).
Moreover, the neutrophil and lymphocyte counts after
ischemic stroke exhibit significant temporal variation
[17], which is also indirectly confirmed by Maestrini et
al. in their evaluation of the influence of the onset-to-
sample time on the neutrophil count, leukocyte count,
and NLR [14]. This suggests that the neutrophil count,
lymphocyte count, and NLR are “dynamic” variables.
However, Maestrini et al. mainly focused on static neu-
trophil count and NLR values at baseline [14], which
may not have dynamically and comprehensively reflected
the patients’ conditions. The clinical application value of
dynamically testing the neutrophil count, lymphocyte
count, and NLR in sICH and worse outcomes may be
meaningful. Holding strict exclusion criteria in our
study, we found that the NLR changed dynamically and
a high NLR at 12–18 h after treatment with IV rtPA was
independently associated with HT after IV rtPA. In
addition, although there were no differences between the
NLR at 12–18 h and the NLR at 36–48 h for auxiliary
diagnosis of PH and sICH, we hold that the NLR at 12–
18 h may be more valuable than that at 36–48 h. First,
the NLR at 12–18 h could be obtained earlier than the
NLR at 36–48 h, which could allow for better monitor-
ing and could better reflect the severity and progression
of disease, helping clinicians to adjust medication regi-
mens and apply related auxiliary examination in time.
Moreover, the NLR at 12–18 h was not inferior to the
NLR at 36–48 h, and it exhibited a tendency to rise su-
perior to the NLR at 36–48 h for diagnosing sICH.
Therefore, we believe that the NLR at 12–18 h is the ap-
propriate selection based on the main concerns in the
present study.
The mechanisms underlying these observations are
not well established, but they seem to be related to the
roles of neutrophils and lymphocytes in ischemic insult
and the disruption of the BBB. Circulating neutrophils
are recruited to the site of cerebral injury shortly after
ischemia occurs and then further contribute to BBB
disruption and tissue damage via a variety of mecha-
nisms [18–20]. Neutrophils have been shown to be an
important source of MMP-9, which may open the BBB
inside the lumen of the blood vessel by acting directly
on tight junction proteins or may be absorbed into
endothelial cells and act on the basement membrane [2].
In a rat cerebral ischemia model, treatments preventing
neutrophil infiltration reduced MMP-9 released in the
brain [21]. Moreover, inhibition or depletion of neutro-
phils can reduce the BBB breakdown and the rate of HT
in ischemic stroke [3, 22]. In contrast, when neutrophils
are increased via lipopolysaccharide or granulocyte
colony-stimulating factor administration, there is an in-
crease in BBB disruption in a mice model [23] and an in-
crease in MMP-9 and rtPA-related HT in a rat stroke
model [4]. In humans with ischemic stroke, early neutro-
philia is associated with larger infarct volumes [24], and
MMP-9-positive neutrophil infiltration has also been asso-
ciated with disruption of the BBB, basal lamina type IV
collagen degradation, and HT [5]. Thus, neutrophils may
mediate HT through neutrophil-derived MMPs in ische-
mic stroke. In addition to neutrophil-derived MMPs,
other factors released from neutrophils after stroke [20],
including ROS, myeloperoxidase, elastase, cathepsin G,
proteinase 3, cytokines, and chemokines, can also disrupt
the neurovascular unit and ultimately result in increased
BBB permeability and HT [17].
In addition to the mechanisms mediated by factors
released from neutrophils, novel aspects of neutrophil
biology may also contribute to ischemic brain injury. Re-
cently, activated neutrophils have been described to form
neutrophil extracellular traps (NETs), a web-like structure
composed of DNA, histones, and specific granule pro-
teins, such as neutrophil elastase and myeloperoxidase, in
response to various stimuli [25]. Recent evidence indicates
that a lack of NETs during myocardial and liver ischemia/
reperfusion (I/R) injury offers significant cardioprotective,
hepatoprotective, and anti-inflammatory effects [26, 27].
Furthermore, extracellular chromatin and histones exacer-
bate cerebral I/R injury in mice [28]. These results suggest
that NETs may play a role in BBB disruption and tissue
damage. Further studies are needed to explore whether
NETs have deleterious effects on HT.
Table 3 Associations of the neutrophil to lymphocyte ratio (NLR) with PH and sICH
PH OR (95 % CI) sICH OR (95 % CI)
Univariate analysis Model 1 Model 2 Univariate analysis Model 1 Model 3
NLRa 1.19 (1.10–1.28)* 1.17 (1.10–1.26)* 1.14 (1.05–1.23)** 1.16 (1.08–1.26)* 1.16 (1.07–1.25)* 1.14 (1.06–1.23)**
NLRb (≥10.59 vs <10.59) 14.22 (5.34–37.91)* 11.86 (4.35–32.36)* 8.50 (2.69–26.89)* 10.06 (3.11–32.52)* 9.55 (2.84–32.04)* 7.93 (2.25–27.99)**
Model 1 bivariate logistic regression analyses with adjustment for age and sex. Model 2 bivariate logistic regression analyses with adjustment for age, sex, ongoing
antiplatelet therapy, and baseline NIHSS. Model 3 bivariate logistic regression analyses with adjustment for age, sex, atrial fibrillation, and ongoing antiplatelet
therapy. CI confidence interval, OR odds ratio, PH parenchymal hemorrhage, sICH symptomatic intracranial hemorrhage
*P < 0.001; **P < 0.05
aNLR as a continuous variable
bNLR as a dichotomous variable
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The lymphocyte counts might serve as an index for
general health, influenced by acute physiologic stress
[29]. Relative lymphopenia on the other hand reflects
the cortisol-induced stress response and sympathetic
tone [30], which can increase the production of proin-
flammatory cytokines that aggravate ischemic injury
[31]. This means that low lymphocyte counts in patients
with HT are not merely an initial response to severe
stroke, but that lymphocytes may be actively involved in
a protective mechanism in the ischemic brain. Experi-
mental evidence suggests that specific subtypes of lym-
phocytes (namely, regulatory T cells) play key roles in
abrogating the inflammatory response and are major
cerebroprotective immunomodulators in acute stroke
[32]. Our findings suggest that lower lymphocyte counts
in patients with HT (data not shown) might have been
the result of fewer regulatory T cells being available to
curtail the inflammatory response, thereby leading to
greater tissue damage. However, other subtypes of lym-
phocytes (namely, proinflammatory lymphocytes) may
have a deleterious effect on I/R injury [33]. It is uncer-
tain which subtype of lymphocytes has a dominant role
in the pathophysiology of cerebral ischemia, and we
demonstrated that a decrease in lymphocytes as a whole
has a negative effect on HT. Further studies are also
needed to elucidate the complex immunomodulatory in-
teractions that occur after stroke.
The NLR reflects the balance between neutrophil and
lymphocyte levels, which may be comprehensively repre-
sent the immunological conditions. In this sense, the
NLR is superior to only the neutrophil count or lympho-
cyte count for distinguishing the occurrence of HT, and
this may also explain why the AUC for the NLR ap-
peared to be greater than those for neutrophil and
lymphocyte counts at each corresponding time point
(Additional file 1: Table S4). On the other hand, inflam-
matory cytokines released by neutrophils may trigger
lymphocyte apoptosis [34]. This suggests that the NLR
may not simply reflect the neutrophil and lymphocyte
counts but also overactivation of neutrophils, thus lead-
ing to a wider gap between the two leukocyte types, and
this also supports the superiority of the NLR.
The main strength of our study is that the clinical
information and blood samples taken at different time
points from all patients were collected in a prospective
fashion with strict exclusion criteria. Previous infections
and early hospital infections in stroke are associated with
an increase in leukocytes and poor outcomes [14, 35].
We limited these potential confounders by ruling out
patients with infection. In addition, our observations of
elevated neutrophil counts in patients with HT (data not
shown) may offer a partial explanation as to why stroke
patients with infection may have poor outcomes. None-
theless, our current findings also have some limitations.
First, the small sample size weakens the statistical
strength of our conclusions. Therefore, further studies
with larger samples are needed. Second, the study popu-
lation included patients receiving a bridging strategy of
the use of IV rtPA followed by endovascular therapy,
which may interfere with our results. Nevertheless, simi-
lar results were found for patients experiencing a bridg-
ing strategy even if the sample was small (data not
shown). On the other hand, this shows that the NLR
may also be applicable to distinguish the presence and
absence of HT in other reperfusion strategies such as
endovascular therapy. Regrettably, a control group that
did not experience reperfusion therapy was not included
in our study. Third, we neither explored the mechanisms
by which neutrophils and lymphocytes affect the BBB
breakdown and HT nor investigated what factors regu-
late the dynamic changes in neutrophil and lymphocyte
counts after ischemic stroke in animal studies. These
will be the focus of our next work.
Conclusions
In conclusion, our results suggest that the NLR is a
dynamic variable and its variation is associated with the
occurrence of HT after thrombolysis in patients with
stroke.
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